ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0049

Enhanced Src Homology Region 2 Domain-containing Phosphatase 1 Activity Ameliorates Murine Inflammatory Arthritis Through the Innate Immune System

Jun Li, Katalin Mikecz and Adrienn Markovics, Rush University Medical Center, Chicago

Meeting: ACR Convergence 2025

Keywords: Animal Model, innate immunity, rheumatoid arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, October 26, 2025

Title: (0049–0066) Rheumatoid Arthritis – Animal Models Poster

Session Type: Poster Session A

Session Time: 10:30AM-12:30PM

Background/Purpose: Src homology region 2 domain-containing phosphatase 1 (SHP-1) is a cytoplasmic protein tyrosine phosphatase expressed in hematopoietic cells (PMID9069265). SHP-1 is a key negative regulator of adaptive and innate immune cell signaling; its function is critical in preventing and eliminating excessive immune cell activation (PMID12490957). Suboptimal SHP-1 function has been linked to autoimmune and inflammatory diseases (PMID27216862). We reported that genetically and pharmacologically enhanced SHP-1 activity reduced disease severity in a T cell-driven murine model of inflammatory arthritis (PMID32586377). Our objective was to determine if the protective role of enhanced SHP-1 activity is mediated by T cells and the adaptive immunity.

Methods: Proteoglycan-induced arthritis (PGIA) was induced in 12-weeks old female wildtype (WT) and Shp1- overexpressing transgenic (Shp1-Tg) mice. For adoptive cell transfer, unseparated spleen cells, regulatory T cells or conventional T cells were isolated from WT or Shp1-Tg mice and transferred to 12-weeks old female mice with Severe Combined Immunodeficiency (SCID). Collagen antibody-induced arthritis (CAIA) was induced in 12-weeks old female WT and Shp1-Tg mice by an antibody cocktail to collagen II. SHP-1 activity was enhanced by regorafenib (REG) treatment of WT mice with CAIA (20 mg/kg/day). Arthritis incidence and severity were determined by Visual Arthritis Score (VAS). Spleens were harvested to determine inflammatory cytokine gene expression by qPCR. Ankle joint histopathology was quantified. Animal experiments were approved by IACUC #23-059 at Rush University Medical Center. Data analysis software: GraphPad Prism v10.1.2. Statistical significance was set at p < 0.05.

Results: In the PGIA adoptive transfer model, SCID mice developed PGIA in each transfer group. PGIA severity in SCID mice was not statistically different following spleen cell transfer or T cell transfer from Shp1-Tg mice, indicating that the protective effect of genetically enhanced SHP-1 activity cannot be transferred by T (or B) cells (Fig 1A-B). In the CAIA model, Shp1-Tg mice showed significantly lower CAIA incidence and severity (Fig 1C) than WT mice. REG treatment of arthritic WT mice significantly reduced CAIA severity. REG treatment also significantly reduced expression of interleukin-1β, IL-6, IL-17 and interferon gamma transcripts. Ankle joint histopathology (synovial thickness, cartilage/bone damage, pannus, inflammatory cell infiltration) was significantly improved after REG treatment (Fig 1D-E).

Conclusion: Enhanced SHP-1 activity was protective/therapeutic in two different murine models of inflammatory arthritis. Since this protective effect was not transferred by spleen cells or T cells from Shp1-Tg mice, it is conceivable that innate immune cells (macrophages, neutrophils) are responsible for the anti-inflammatory effect of enhanced SHP-1 activity. Given the significant role of macrophages and neutrophils in RA, future studies will explore if enhanced SHP-1 activity in these cells can be utilized as a cell-based therapeutic approach in RA.

Supporting image 1Figure 1. The anti-arthritic effect of SHP-1 overexpression is mediated by the innate immune system. A: Significantly reduced PGIA severity in spleen cell donor Shp1-Tg mice (12-weeks old female, n=10-12/group). B: No significant difference in PGIA severity in spleen cell recipient SCID mice (12-weeks old female, n=6-7/group). C: Shp1-Tg mice show significantly reduced CAIA severity compared to WT mice (n=10/group). D-E: Representative images of the tibiotarsal joint of WT mice with CAIA and treated with vehicle (D) or SHP-1 activator regorafenib (E). Alcian blue/hematoxylin/orange G staining. (p* < 0.05, p** < 0.01;two-way ANOVA followed by Sidak`s multiple comparison).


Disclosures: J. Li: None; K. Mikecz: None; A. Markovics: None.

To cite this abstract in AMA style:

Li J, Mikecz K, Markovics A. Enhanced Src Homology Region 2 Domain-containing Phosphatase 1 Activity Ameliorates Murine Inflammatory Arthritis Through the Innate Immune System [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/enhanced-src-homology-region-2-domain-containing-phosphatase-1-activity-ameliorates-murine-inflammatory-arthritis-through-the-innate-immune-system/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/enhanced-src-homology-region-2-domain-containing-phosphatase-1-activity-ameliorates-murine-inflammatory-arthritis-through-the-innate-immune-system/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology